Injectable GLP-1 medications generally produce greater average weight reductionlargely because subcutaneous delivery ensures a consistent therapeutic dose
Obesity: global epidemiology and pathogenesis
It is not positioned for supplement use, medical use, treatment use, prevention use, cosmetic use, skin use, anti-aging use, recovery use, performance use, or any human or animal application
GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and GIP/GLP-1 dual agonists (tirzepatide) carry the clinical evidence: STEP (semaglutide, NEJM 2021), SURMOUNT (tirzepatide, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024)
They act like sidekicks, lending a hand to support your bodys natural rhythms and keep your blood sugar on track